Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
American Pharmaceutical Partners, Inc.
ANDA approval granted for valproate sodium injection
July 30th, 2003
American Pharmaceutical Partners, Inc., (APPX) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of valproate sodium injection. Valproate sodium injection, the generic equivalent of Abbott Laboratories' Depacon Sodium Injection, is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. "Valproate represents the fifth product approval APP has received thus far in 2003 and complements our growing critical care offering," said Patrick...
Source: Biotech Week (2003-07-30)
|
